What Does Duloxetine Treat? Depression, Pain & More

Duloxetine is approved to treat a surprisingly wide range of conditions: major depressive disorder, generalized anxiety disorder, diabetic nerve pain, fibromyalgia, chronic musculoskeletal pain, and (in some countries) stress urinary incontinence. It also sees significant off-label use for conditions like chemotherapy-induced nerve pain. The reason one drug spans so many seemingly unrelated problems comes down to how it works in the brain and spinal cord, and understanding that mechanism helps explain both its benefits and its limitations.

How Duloxetine Works

Duloxetine belongs to a class of drugs called serotonin-norepinephrine reuptake inhibitors, or SNRIs. It blocks the recycling of two chemical messengers in the nervous system: serotonin and norepinephrine.¹ When these chemicals stick around longer in the gaps between nerve cells, mood-regulating circuits in the brain become more active, which is the antidepressant and anti-anxiety effect.

But serotonin and norepinephrine also play a major role in how your spinal cord processes pain signals. Your brain has built-in pain-dampening pathways that run downward through the spinal cord, and both of these chemicals help power those pathways. By boosting their levels, duloxetine strengthens the body’s own ability to dial down incoming pain signals.² That dual action on mood and pain is what makes the drug useful across such different diagnoses. In clinical trials, pain relief from duloxetine has been observed as early as the first week of treatment, which is faster than the usual timeline for antidepressant effects to kick in.³

Major Depressive Disorder

Depression was the first condition duloxetine was approved for, and it remains one of the most common reasons it is prescribed. In placebo-controlled trials, duloxetine at 60 mg daily significantly improved depression symptoms and led to higher remission rates than placebo.⁴ “Remission” in these studies means a person’s depression score dropped low enough to be considered essentially symptom-free, not just improved.

When compared head-to-head with SSRIs (the older, more commonly prescribed class of antidepressants), duloxetine performs about the same overall. In a pooled analysis, remission rates were roughly 40% for duloxetine and 38% for SSRIs, with both well ahead of placebo at about 28%. The difference between duloxetine and SSRIs was not statistically meaningful for most patients. However, for people with more severe depression, duloxetine pulled ahead, with remission rates of about 36% compared to about 29% for SSRIs.⁵ This makes duloxetine a particularly relevant option when depression is moderate to severe, or when an SSRI has already been tried without success.

When Depression Comes With Physical Pain

One of duloxetine’s more distinctive features is its effectiveness for the aches and pains that often accompany depression. Many people with major depression experience unexplained back pain, shoulder pain, or generalized body soreness, and these physical symptoms can make depression harder to treat. In trials, duloxetine reduced overall pain, back pain, and shoulder pain significantly more than placebo in depressed patients.⁶

An interesting question researchers have explored is whether duloxetine relieves these pains directly, or whether the pain just gets better because depression gets better. The answer turns out to be both, but the timing shifts. In the first week of treatment, about three-quarters of the drug’s pain-relieving effect is direct, meaning it works on pain pathways independent of mood improvement. By week eight, that flips: most of the pain relief comes indirectly through the improvement in depression itself.⁷ This means duloxetine is doing genuinely different things at different stages of treatment, and it helps explain why some people notice the pain relief before their mood lifts.

Generalized Anxiety Disorder

Duloxetine is also approved for generalized anxiety disorder (GAD), a condition characterized by persistent, hard-to-control worry accompanied by physical symptoms like muscle tension, restlessness, and sleep trouble. In clinical trials, duloxetine significantly improved anxiety scores and overall functioning compared to placebo, including work performance, social life, and family relationships.⁸

Perhaps more compelling is the evidence for relapse prevention. In a study where patients with GAD who had responded to duloxetine were then randomly switched to either continued duloxetine or placebo, about 42% of those switched to placebo relapsed, compared to only about 14% of those who stayed on duloxetine.⁹ That three-fold difference makes a strong case for continuation treatment in people whose anxiety has responded well.

Diabetic Peripheral Neuropathy

Nerve damage from diabetes is one of the conditions where duloxetine has the strongest evidence. The burning, tingling, and shooting pains of diabetic neuropathy can be debilitating, and duloxetine is one of only a handful of drugs specifically approved for it. A Cochrane review, which is the gold standard for evidence synthesis, found that duloxetine at 60 mg daily made patients roughly 73% more likely to achieve at least a 50% reduction in pain compared to placebo over 12 weeks. On average, about one in five people who take duloxetine for this condition will get meaningful relief that they would not have gotten from a placebo.¹⁰ A separate meta-analysis confirmed significant pain reduction compared to placebo.¹¹

Pain relief begins within the first week and holds through longer treatment periods. In randomized trials, both 60 mg once daily and 60 mg twice daily outperformed placebo, with no meaningful difference between the two dosing regimens on most pain measures.¹² The drug also did not appear to worsen blood sugar control, which matters for a population already managing diabetes.¹³

How It Compares to Gabapentin and Pregabalin for Nerve Pain

Gabapentin and pregabalin are the other medications commonly used for diabetic nerve pain, so a natural question is how duloxetine stacks up. The answer is somewhat anticlimactic: in head-to-head comparisons, pain relief is broadly similar across all three drugs. A meta-analysis comparing duloxetine and gabapentin found no significant difference in pain scores or overall response rates.¹⁴ A three-way comparison trial found that all three drugs significantly reduced pain from baseline with no significant difference between groups, though pregabalin tended to work a bit faster in the first few weeks.¹⁵

Where duloxetine had a notable edge was in side effects: it was associated with significantly fewer adverse reactions than gabapentin and also improved sleep interference scores more.¹⁴ Duloxetine may also be the more practical choice if depression or anxiety coexists with nerve pain, since it treats both at once. Gabapentin and pregabalin do not have antidepressant effects.

Fibromyalgia

Fibromyalgia involves widespread pain, fatigue, and cognitive difficulties, and it often overlaps with depression. Duloxetine is one of three drugs approved in the United States specifically for fibromyalgia. In a pooled analysis of four clinical trials, duloxetine significantly reduced pain and improved overall functioning, quality of life, and depression scores compared to placebo.¹⁶ The drug has demonstrated efficacy in fibromyalgia patients regardless of whether they also have major depression.¹⁷

One nuance worth noting: the evidence is stronger for women than for men. In an early pivotal trial, duloxetine-treated women showed significant improvement across most measures, but the small number of men in the study (only 12 per group) did not show significant improvement on any measure.¹⁸ That could be a real sex difference or just a problem of sample size. Either way, the vast majority of fibromyalgia patients are women, so the evidence base is weighted accordingly.

Chronic Musculoskeletal Pain

Duloxetine is approved for chronic musculoskeletal pain, which primarily means osteoarthritis (especially knee osteoarthritis) and chronic low back pain. A systematic review and meta-analysis found that duloxetine had modest to moderate effects on pain relief, physical function, mood, and quality of life for both conditions, with generally mild side effects.¹⁹ For knee osteoarthritis specifically, pooled data from five randomized trials showed moderate, statistically significant pain reduction over 12 to 14 weeks, along with modest improvements in function.²⁰

The word “modest” keeps appearing in these reviews, and it is worth being honest about. Duloxetine is not going to replace a knee. For someone with severe structural joint damage, the effect may feel underwhelming. But for people whose pain has a significant central-sensitization component, meaning the nervous system is amplifying pain signals beyond what the tissue damage alone would explain, duloxetine can make a real difference. It is often prescribed as an add-on when anti-inflammatory drugs alone are not enough.

Stress Urinary Incontinence

This one surprises most people. Duloxetine is approved in parts of Europe and elsewhere (but not in the United States) for stress urinary incontinence, which is the involuntary leakage of urine during coughing, sneezing, or exercise. The mechanism involves the same two neurotransmitters working in a different location: serotonin and norepinephrine boost the activity of a nerve that controls the urethral sphincter, the muscle that holds urine in. By increasing the tone of that sphincter during storage without interfering with normal voiding, duloxetine reduces leakage episodes.²¹ Animal studies showed dramatic increases in both bladder capacity and sphincter activity.²² The drug did not gain approval for this indication in the U.S. partly due to concerns about nausea-related dropout rates in trials, but it remains a recognized treatment option in many other countries.

Off-Label Uses

Duloxetine also sees meaningful off-label use, particularly for chemotherapy-induced peripheral neuropathy (CIPN). Many cancer survivors develop painful numbness and tingling in their hands and feet from certain chemotherapy agents, and there are few effective treatments. In a randomized crossover trial, patients who received duloxetine were significantly more likely to experience clinically meaningful pain reduction than those who received placebo. Nearly 60% of duloxetine-treated patients experienced some decrease in pain, compared to 38% on placebo, and those receiving duloxetine were roughly twice as likely to achieve a 50% pain reduction.²³ Based on this evidence, duloxetine is now recommended by oncology guidelines as a treatment option for CIPN, even though it does not carry a formal approval for that use.

Common Side Effects

No honest discussion of duloxetine is complete without talking about side effects. In a large pooled analysis across all approved indications, about 72% of duloxetine-treated patients reported at least one side effect, compared to about 57% on placebo.²⁴ That gap is real, though many of these side effects are mild and tend to fade over the first few weeks.

The most common side effects that occur significantly more often with duloxetine than placebo are:

Nausea: the most frequent complaint, occurring in roughly 23% of patients on duloxetine versus about 7% on placebo. It is usually mild to moderate and tends to settle within the first week or two.
Dry mouth, constipation, and decreased appetite: common but generally manageable gastrointestinal effects.
Dizziness and somnolence: these affect a smaller percentage but can be bothersome, especially early in treatment.
Insomnia, fatigue, and increased sweating: paradoxically, the drug can cause either sleepiness or difficulty sleeping, depending on the person.

Side effects led to roughly 10% of duloxetine patients stopping the drug in pooled depression trials, versus about 4% on placebo.²⁵ The pattern of side effects differs somewhat by condition. Patients being treated for fibromyalgia had the highest overall side-effect rates, while those being treated for osteoarthritis pain had the lowest.²⁴

Stopping Duloxetine Safely

Duloxetine has a well-documented discontinuation syndrome. If you stop the drug abruptly, you may experience dizziness, nausea, headache, tingling sensations, vomiting, irritability, or nightmares. In pooled data from six short-term trials, about 44% of patients stopping duloxetine abruptly reported at least one of these symptoms, compared to about 23% stopping placebo. Dizziness was the most common, affecting about 12% of patients on abrupt discontinuation. The good news is that most of these symptoms resolved within a week and were rated as mild to moderate. Higher doses, particularly 120 mg daily, were associated with more discontinuation symptoms.²⁶

The practical takeaway is straightforward: do not stop duloxetine cold turkey. Taper gradually under medical supervision. Most prescribers will reduce the dose in steps over at least a couple of weeks, and sometimes longer for people who have been on the drug for an extended period or who are sensitive to dose changes.

Liver Safety

Duloxetine carries a warning about liver injury, and this deserves some context. Case reports have documented instances where duloxetine caused clinically significant liver damage, including in patients without pre-existing liver disease.²⁷ In a case series from a drug-induced liver injury registry, most affected patients developed jaundice, and the median time from starting the drug to liver injury onset was about 50 days. All patients recovered, and none required a liver transplant, though some had serious complications including kidney problems.²⁸

A large retrospective study looking at health insurance claims data found no cases of liver failure or liver-related death among duloxetine users. There were slightly higher rates of other liver injuries compared to venlafaxine and SSRIs, but the differences were not statistically significant and remained consistent with chance.²⁹ In practical terms, serious liver injury from duloxetine is rare but real. The drug should not be used in people with significant liver disease or heavy alcohol use, and clinicians should monitor liver function, particularly in the first few months.

Drug Interactions Worth Knowing

Duloxetine is processed in the liver by a specific enzyme system, and it also inhibits one of those enzymes, called CYP2D6. Its inhibition of CYP2D6 is moderate, falling somewhere between paroxetine (a strong inhibitor) and sertraline (a weak one).³⁰ This means duloxetine can raise the blood levels of other drugs that rely on CYP2D6 for clearance. That list includes certain beta-blockers, some antipsychotics, and codeine-type painkillers (though in the case of codeine, the interaction actually reduces its effectiveness, since codeine needs CYP2D6 to be converted into its active form).

On the flip side, drugs that strongly inhibit CYP2D6 or another enzyme called CYP1A2 can raise duloxetine levels. The antibiotic fluvoxamine and the antidepressant paroxetine are well-known examples. Lab studies have shown that duloxetine’s inhibition of liver enzymes is reversible rather than permanent, which is somewhat reassuring.³¹ Still, if you are on multiple medications, your prescriber should review potential interactions before starting duloxetine.

Fall Risk in Older Adults

For older adults, falls are a significant concern with any drug that affects the central nervous system. In a 24-week trial, about 25% of older patients on duloxetine experienced a fall, compared to about 16% on placebo.³² A larger observational study compared duloxetine to gabapentin in older adults and found that gabapentin users actually had a lower hazard of fall-related medical visits, though there was no difference in severe falls.³³ This does not mean duloxetine should be avoided in older patients, but it does mean the benefit-risk calculation deserves more attention. Starting at a lower dose and monitoring for dizziness or unsteadiness in the first weeks is reasonable practice.

Pregnancy and Breastfeeding

Data on duloxetine during pregnancy is limited compared to older antidepressants like sertraline or fluoxetine. A review of available evidence found that duloxetine use during pregnancy may be associated with an increased risk of spontaneous abortion but not with major birth defects. Late-pregnancy exposure may lead to poor neonatal adaptation syndrome, where newborns have temporary breathing difficulties or jitteriness, though how often this occurs is not well established.³⁴

Breastfeeding appears to be lower risk. Duloxetine is present in breast milk, with steady-state concentrations about one-quarter of those in maternal blood.³⁵ In the one detailed case report measuring infant exposure, the amount of drug reaching the infant through breast milk was less than 1% of the mother’s weight-adjusted dose, with no adverse effects noted in the infant.³⁶ For women who are already stable on duloxetine and want to breastfeed, this is generally considered reassuring, though individual risk assessment with a prescriber remains important.

Weight Changes Over Time

Weight gain is a common concern with antidepressants, and duloxetine performs relatively well on this front. In short-term treatment, patients tend to lose a small amount of weight, likely related to the appetite-suppressing effects of nausea early on. Over longer treatment periods, modest weight gain appears. In a 52-week open-label study, the average weight gain was about 1.1 kg (roughly 2.4 pounds). At the standard dose of 60 mg once daily, the amount of weight gained over about eight months was not significantly different from placebo. At higher doses, weight gain was statistically significant but still small, roughly similar to what was seen with paroxetine.³⁷ For most people, duloxetine’s effect on weight is minimal compared to some other antidepressants that can cause gains of several kilograms or more.